First, we evaluated the frequency of CD4+FoxP3+ Tregs in melanoma patients and healthy donors, and as previously reported[9], we found an increase in Tregs in the melanoma patients compared to healthy donors (n = 21 and 19, respectively); P = 0.007; Figure 3A). This evidence concerns the gene CD4 and melanoma.